Navigation Links
INNOPHARMA Receives FDA Approval of Generic Levetiracetam Injection

PISCATAWAY, N.J., Aug. 8, 2011 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of its Abbreviated New Drug Application (ANDA) for levetiracetam injection (the generic equivalent of Keppra® injection from UCB Inc).

As the developer of this generic injectable drug, INNOPHARMA entered into a license agreement with X-GEN Pharmaceuticals, Inc. for marketing and product distribution in the US.


INNOPHARMA is a sterile product development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at    

About X-GEN:

X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN's expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, and inhalants. For more information about X-GEN Pharmaceuticals, Inc.  call (866) 390-4411, or visit the web-site at

Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. INNOPHARMA Receives First FDA Approval
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc.
4. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
5. Ontario Institute for Cancer Research Receives $420 Million Over Five Years for Important Cancer Research in Ontario
6. Good Samaritan Hospitals Wound and Hyperbaric Institute Receives Accreditation from Undersea and Hyperbaric Medical Society, Recognizing Advanced Care
7. Once-Daily Welchol® (colesevelam HCl) for Oral Suspension Receives FDA Approval To be Mixed With Fruit Juice or Diet Soft Drinks
8. Nephros Receives 510k Approval to Market Additional Ultrafiltration Products
9. BioMedix™ Receives Patent for Its Innovative Collaborative Care Business Method
10. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
11. Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
Post Your Comments:
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):